Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Kahn

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
AIDS (London, England)|May 11, 2002
Use of laboratory tests and clinical symptoms for identification of primary HIV infectionFrederick M Hecht, Michael P Busch, Bhupat Rawal, et al.
The Journal of Infectious Diseases|May 1, 1995
Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trialJ O Kahn, K S Steimer, J Baenziger, et al.
The Journal of Infectious Diseases|February 22, 2001
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP StudyJ O Kahn, J N Martin, M E Roland, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|June 1, 1995
Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials GroupJ Paredes, J O Kahn, W P Tong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1991
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trialL D Kaplan, J O Kahn, S Crowe, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2012
The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health settingElvin H Geng, C Bradley Hare, James O Kahn, et al.
JAMA|July 4, 2002
Time trends in primary HIV-1 drug resistance among recently infected personsRobert M Grant, Frederick M Hecht, Maria Warmerdam, et al.
The New England Journal of Medicine|August 27, 1992
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials GroupJ O Kahn, S W Lagakos, D D Richman, et al.
The Journal of Infectious Diseases|July 10, 2004
HIV RNA testing in the context of nonoccupational postexposure prophylaxisMichelle E Roland, Tarek A Elbeik, James O Kahn, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
AIDS (London, England)|May 11, 2002
Use of laboratory tests and clinical symptoms for identification of primary HIV infectionFrederick M Hecht, Michael P Busch, Bhupat Rawal, et al.
The Journal of Infectious Diseases|May 1, 1995
Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trialJ O Kahn, K S Steimer, J Baenziger, et al.
The Journal of Infectious Diseases|February 22, 2001
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP StudyJ O Kahn, J N Martin, M E Roland, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|June 1, 1995
Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials GroupJ Paredes, J O Kahn, W P Tong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1991
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trialL D Kaplan, J O Kahn, S Crowe, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2012
The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health settingElvin H Geng, C Bradley Hare, James O Kahn, et al.
JAMA|July 4, 2002
Time trends in primary HIV-1 drug resistance among recently infected personsRobert M Grant, Frederick M Hecht, Maria Warmerdam, et al.
The New England Journal of Medicine|August 27, 1992
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials GroupJ O Kahn, S W Lagakos, D D Richman, et al.
The Journal of Infectious Diseases|July 10, 2004
HIV RNA testing in the context of nonoccupational postexposure prophylaxisMichelle E Roland, Tarek A Elbeik, James O Kahn, et al.
Pageof 9